URGN · UroGen Pharma Ltd.
$40.97
-1.40% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
27.8
Dividend yield
—
Beta
1.58
Avg volume
1M
Employees
0K
2D change
1.20%
5D change
-2.45%
10D change
3.06%
30D change
20.03%
60D change
47.39%
MTD change
9.28%
YTD change
77.03%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — URGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-21
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | Guggenheim | Maintains | Buy | $32.00 → $42.00 |
| 2026-07-16 | Oppenheimer | Maintains | Outperform → Outperformer | $40.00 → $50.00 |
| 2026-06-03 | HC Wainwright & Co. | Reiterates | Buy | $45.00 |
| 2026-05-18 | HC Wainwright & Co. | Reiterates | Buy | $45.00 |
| 2026-05-11 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $45.00 |
| 2026-05-07 | Oppenheimer | Maintains | Outperform | $34.00 → $40.00 |
| 2026-03-31 | D. Boral Capital | Maintains | Buy | $33.00 |
| 2026-03-02 | D. Boral Capital | Maintains | Buy | $33.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 20.8% above the 50-day MA ($33.84).
- Price vs 200-day MA: Trading 66.0% above the 200-day MA ($24.62).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.16) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($16.42) and high ($43.78).
URGN Price Chart
Loading chart for URGN…
Fundamentals
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.